drugset / Trial / NCT04402723
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
Timeline
- Start
- 2018-11-06
- Primary completion
- 2022-02-09
- Completion
- 2022-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 0.2 g | Oral |
| Subject | Donafenib | Small molecule | 0.3 g | Oral |